)
Visual
earnings real time
Amphastar Pharmaceuticals
Amphastar Pharmaceuticals (AMPH) investor relations material
Amphastar Pharmaceuticals 44th Annual J.P. Morgan Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.44th Annual J.P. Morgan Healthcare Conference summary14 Jan, 2026
Strategic direction, business model, and integration
Operates a fully integrated model with in-house R&D, manufacturing, and marketing, supporting both internal development and strategic acquisitions.
Maintains full control over quality and compliance across all stages, with vertically integrated operations for flexibility and scalability.
Dual growth strategy: internal product development and targeted acquisitions, such as Baqsimi and facilities in the US and France.
Expanded international footprint to over 26 countries, leveraging acquisitions to support proprietary launches.
Focuses on high-quality, high-efficiency, and high-technology products for competitive advantage.
Growth strategy, financial performance, and market strategy
Revenue grew from $295M in 2018 to $732M in 2024, with adjusted net income margin rising to 27.4%.
Annual EPS increased from $0.64 in 2020 to $4.5 in 2024, with a 20% CAGR in revenue and 57% CAGR in adjusted EPS.
R&D investment reached $351M over five years, with annual R&D expenses rising and expected to increase further.
2026 revenue growth forecast revised to mid-single digit to low double digits, driven by new launches and expanded sales.
Strategic withdrawal from unprofitable international Baqsimi markets to improve margins.
Pipeline evolution, R&D highlights, and innovation
By 2026, proprietary and biosimilar products are projected to comprise 85% of the pipeline, up from 37% in 2021.
Proprietary pipeline includes intranasal epinephrine, reformulated Primatene Mist, and several in-licensed NCEs.
Promising peptide and biologics pipeline targets oncology, ophthalmology, endocrinology, and rheumatology.
AMP-109 demonstrated >99% tumor inhibition in preclinical pancreatic cancer models; AMP-110 is a fully synthetic corticotropin analog with reduced impurity and viral risk.
Proprietary delivery technologies include intranasal and metered dose inhaler platforms, supporting innovation in drug administration.
Quantify R&D's role in proprietary pipeline shift
Differentiate AMP-107 and AMP-110 market value
Commercialization strategy for 2026-27 launches
What drives the 2026 proprietary pipeline target?
Why withdraw BAQSIMI from some international markets?
How will AMP-110 leverage prior China studies?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- CSIG
IPO seeks $922M+ for tech-driven capital markets platform; strong growth, high dilution, controlled structure. - SVEA
Net profit rose 41% to 10,910 MSEK in 2025, with a proposed 1,338 MSEK dividend. - SWK
Gross margin and net income rose, with CAM divestiture set to reduce debt and boost 2026 outlook. - TOM2
Record Automotive backlog and margin gains offset a 3% revenue decline in 2025. - CMBT
Q1 profit, Golden Ocean merger, and decarbonization drive strong outlook. - CBT
Adjusted EPS down 13% to $1.53 as Battery Materials growth offset Reinforcement Materials decline. - ADVENZYMES
Q3 FY26 revenue up 2% YoY, PAT up 11%, with wind power SPV investment approved. - SIMO
Q4 2025 revenue and margins surged on SSD, eMMC/UFS, and automotive growth; 2026 outlook strong. - FSV
Annual revenue up 5% to $5.50B; Adjusted EBITDA and EPS both saw double-digit growth. - QLINEA
Over 400% revenue growth in 2025, with US expansion and breakeven targeted for 2027.
Next Amphastar Pharmaceuticals earnings date
Q4 202527 Feb, 2026
Amphastar Pharmaceuticals
Next Amphastar Pharmaceuticals earnings date
Q4 202527 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
)
Frequently asked questions
Amphastar Pharmaceuticals Inc. is a specialty pharmaceutical company engaged in the development, manufacture, and marketing of generic and proprietary injectable, inhalation, and intranasal products. The company focuses on producing pharmaceuticals for hospital, emergency, and clinical use, including treatments for respiratory conditions, diabetes, and pain management. Amphastar operates manufacturing and research facilities to support its product portfolio and pipeline development. Amphastar Pharmaceuticals Inc. is headquartered in Rancho Cucamonga, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage